Nishioka K, Hashizume M, Kitano S, Ohta M, Ueno K, Tomikawa M, Higashi H, Okamura T, Sugimachi K
Second Department of Surgery, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Surg Today. 1996;26(1):53-6. doi: 10.1007/BF00311993.
We describe herein the case of a 57-year-old man with thalassemia who developed acute liver failure after undergoing endoscopic injection sclerotherapy (EIS) to control hemorrhage from a ruptured esophageal varix. The patient, who had been confirmed as having liver cirrhosis due to chronic hepatitis C with thalassemia in 1989, was admitted to our department to undergo EIS for esophageal varices, at which time his serum total bilirubin level was 5.5 mg/dl. As a small amount of hematemesis occurred just after a percutaneous transhepatic portography was performed, emergency EIS was carried out, following which the serum total bilirubin level markedly increased, mainly with a direct fraction, until it reached 70 mg/dl. The patient eventually died from acute liver failure with extreme hyperbilirubinemia on the 27th day after experiencing hematemesis despite all treatment. This unfortunate case demonstrates that sclerotherapy could be an inappropriate method of treatment for patients with hemolytic disease.
我们在此描述一例57岁的地中海贫血男性患者,其在接受内镜注射硬化疗法(EIS)以控制破裂食管静脉曲张出血后发生急性肝衰竭。该患者于1989年被确诊为因慢性丙型肝炎合并地中海贫血导致肝硬化,因食管静脉曲张入住我科接受EIS治疗,当时其血清总胆红素水平为5.5mg/dl。在经皮经肝门静脉造影术后不久发生少量呕血,遂进行了紧急EIS,之后血清总胆红素水平显著升高,主要是直接胆红素升高,直至达到70mg/dl。尽管进行了所有治疗,患者在呕血后第27天最终死于伴有极高胆红素血症的急性肝衰竭。这一不幸案例表明,硬化疗法对于溶血性疾病患者可能是一种不恰当的治疗方法。